title: Comparison of a non-preserved 0.1% T-Gel eye gel (single dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patients.
abstract: OBJECTIVE
  This comparative, open design, phase III study was to assess the non-inferiority of the non-preserved T-Gel 0.1% single dose unit (SDU) versus its preserved multidose (MD) reference.
  
  
  METHODS
  175 patients with bilateral POAG or OHT were randomised: 87 patients were to receive one drop daily of T-Gel 0.1% MD and 88 patients were to receive one drop daily of T-Gel 0.1% SDU, for a treatment period of 12 weeks. The primary efficacy variable was the change in intraocular pressure (IOP) in the worse eye between the baseline and the last assessment. Subjective and objective ocular signs as well as adverse events were recorded for safety. Global tolerance was assessed by the investigator and by the patient.
  
  
  RESULTS
  The mean percentage reduction from baseline IOP was 24% for both treatments groups, which was consistent with previous studies. The safety results were comparable in both treatment groups. Because of gel formulation, mild short lasting episodes of blurred vision occurred for about 20% of patients. The global tolerance assessment reported that both treatments were well tolerated.
  
  
  CONCLUSIONS
  The overall study results demonstrated that T-Gel 0.1% SDU is not inferior to T-Gel 0.1% MD.
authors.affiliation: Department of Ophthalmology, Bristol Eye Hospital, UK. david.easty@bristol.ac.uk
authors.forename: D L
authors.initials: DL
authors.lastname: Easty
authors.forename: G
authors.initials: G
authors.lastname: Nemeth-Wasmer
authors.forename: J-P
authors.initials: JP
authors.lastname: Vounatsos
authors.forename: B
authors.initials: B
authors.lastname: Girard
authors.forename: N
authors.initials: N
authors.lastname: Besnainou
authors.forename: P
authors.initials: P
authors.lastname: Pouliquen
authors.forename: L
authors.initials: L
authors.lastname: Delval
authors.forename: J-F
authors.initials: JF
authors.lastname: Rouland
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D000704:Analysis of Variance; D000959:Antihypertensive Agents / Q000097:blood / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005782:Gels; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy*; D009883:Ophthalmic Solutions / Q000627:therapeutic use; D011310:Preservatives, Pharmaceutical / Q000627:therapeutic use; D013999:Timolol / Q000097:blood / Q000627:therapeutic use*
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D005782:Gels; D009883:Ophthalmic Solutions; D011310:Preservatives, Pharmaceutical; D013999:Timolol